Mohammad-Javad Khosousi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mohammad-Javad Khosousi has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Ali Bidari
Department of Rheumatology, Iran University of Medical Sciences, Tehran, Iran
4 shared publications - Banafsheh Ghavidel-Parsa
Rheumatology Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
4 shared publications - Sepehr Tohidi
Student Research Committee, School of Medicine, Guilan Universtiy of Medical Sciences, Rasht, Iran
2 shared publications - Abinash Mahapatro
SIU School of Medicine, Springfield, IL, USA
1 shared publication - Ali Fatehi Hassanabad
Section of Cardiac Surgery, Columbia University Vagelos College of Physicians and Surgeons, New York City, New York, USA
1 shared publication - Ali Montazeri
Population Health Research Group, Health Metrics Research Center, Institute for Health Sciences Research, ACECR, Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 14 July 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (14) , 2103
Artificial Intelligence and Healthcare Policy: A Bibliometric Analysis of Global Research Trends
Background: Artificial intelligence is increasingly influencing health care and policy, yet the global research landscape linking artificial intelligence and health care policy remains underexplored. This study aimed to map publication trends, major contributors, collaboration networks, citation structures, and emerging themes in this field. Methods: A bibliometric analysis was conducted using the Web of Science Core Collection. The search was performed on 3 May 2026, and covered publications from 2000 to 3 May 2026. The final dataset included 347 peer-reviewed English-language original research and review articles. Biblioshiny, VOSviewer, and CiteSpace were used to analyze publication trends, country and institutional contributions, author and journal productivity, collaboration networks, citation and co-citation structures, keyword patterns, and thematic evolution. Results: Publications increased markedly after 2020 and reached their highest annual output in 2025. The 2026 publication count was lower because data for that year were partial at the time of database retrieval. Researchers from 82 countries and 900 institutions contributed to the field, with the United States leading in output, followed by China, England, Canada, and India. Harvard Medical School was the most productive institution, whereas Harvard University had the highest institutional centrality. Frontiers in Public Health published the most articles, and PLOS ONE was the most frequently co-cited journal. The most cited article was “Artificial intelligence and the future of global health.” Key research themes included machine learning, COVID-19, health policy, risk, large language models, interpretable machine learning, neural network-assisted screening, socioeconomic perspectives, and public health applications. Conclusions: Research on artificial intelligence and health care policy has expanded rapidly, particularly in recent years, and is increasingly centered on predictive modeling, public health decision-making, and emerging artificial intelligence technologies. These findings highlight influential contributors, evolving themes, and future directions for researchers, policymakers, and health care leaders.
- 14 July 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (14) , 2103
Open AccessArtificial Intelligence and Healthcare Policy: A Bibliometric Analysis of Global Research Trends
Background: Artificial intelligence is increasingly influencing health care and policy, yet the global research landscape linking artificial intelligence and health care policy remains underexplored. This study aimed to map publication trends, major contributors, collaboration networks, citation structures, and emerging themes in this field. Methods: A bibliometric analysis was conducted using the Web of Science Core Collection. The search was performed on 3 May 2026, and covered publications from 2000 to 3 May 2026. The final dataset included 347 peer-reviewed English-language original research and review articles. Biblioshiny, VOSviewer, and CiteSpace were used to analyze publication trends, country and institutional contributions, author and journal productivity, collaboration networks, citation and co-citation structures, keyword patterns, and thematic evolution. Results: Publications increased markedly after 2020 and reached their highest annual output in 2025. The 2026 publication count was lower because data for that year were partial at the time of database retrieval. Researchers from 82 countries and 900 institutions contributed to the field, with the United States leading in output, followed by China, England, Canada, and India. Harvard Medical School was the most productive institution, whereas Harvard University had the highest institutional centrality. Frontiers in Public Health published the most articles, and PLOS ONE was the most frequently co-cited journal. The most cited article was “Artificial intelligence and the future of global health.” Key research themes included machine learning, COVID-19, health policy, risk, large language models, interpretable machine learning, neural network-assisted screening, socioeconomic perspectives, and public health applications. Conclusions: Research on artificial intelligence and health care policy has expanded rapidly, particularly in recent years, and is increasingly centered on predictive modeling, public health decision-making, and emerging artificial intelligence technologies. These findings highlight influential contributors, evolving themes, and future directions for researchers, policymakers, and health care leaders.
- Open Access
- 3 May 2022
- Published by Springer Nature in BMC Rheumatology
- Vol. 6 (1) , 1-9
Validity and reliability of the Persian version of illness invalidation inventory (3*I) among patients with non-inflammatory rheumatic painful disorders
Background: The Invalidation Illness Inventory (3*I) is an instrument that assesses invalidation (including discounting and lack of understanding dimensions) experienced by patients with rheumatic disorders. This study aimed to translate and validate the 3*I in Iran. Methods: Following translation of the 3*I into the Iranian language (Persian), a cross-sectional study was conducted. A consecutive sample of females with chronic non-inflammatory rheumatic painful diseases completed the questionnaire. Patients also completed the Revised Symptom Impact Questionnaire (SIQR) and the Short Form Health Survey-12 (SF-12). To examine convergent validity, the correlation between the 3*I, the SIQR, and the SF-12 was assessed. The reliability of the 3*I was examined by internal consistency (the Cronbach's alpha coefficient) and intraclass correlation coefficient (ICC). Results: In all 196 patients participated in the study. The mean (SD) age of patients was 45.62 ± 10.70 years. Several significant correlations between the Invalidation Illness Inventory (discounting/lack of understanding) with the symptom impact (SIQR) and the short form health survey (SF-12) were observed lending support to the convergent validity of the 3*I. The Cronbach’s alpha coefficients were acceptable for most dimensions and sources, ranging from 0.52 to 0.88. Most ICC values for the dimensions of 3*I were above 0.75. Conclusions: The findings indicated that the Persian version of Illness Invalidation Inventory (3*I) is a valid instrument for invalidation assessment in patients with chronic pain. Given the high frequency of perceived invalidation among patients with rheumatic painful disorders, serious attention is needed to the issue in clinical and research settings.
- 3 May 2022
- Published by Springer Nature in BMC Rheumatology
- Vol. 6 (1) , 1-9
Open AccessValidity and reliability of the Persian version of illness invalidation inventory (3*I) among patients with non-inflammatory rheumatic painful disorders
Background: The Invalidation Illness Inventory (3*I) is an instrument that assesses invalidation (including discounting and lack of understanding dimensions) experienced by patients with rheumatic disorders. This study aimed to translate and validate the 3*I in Iran. Methods: Following translation of the 3*I into the Iranian language (Persian), a cross-sectional study was conducted. A consecutive sample of females with chronic non-inflammatory rheumatic painful diseases completed the questionnaire. Patients also completed the Revised Symptom Impact Questionnaire (SIQR) and the Short Form Health Survey-12 (SF-12). To examine convergent validity, the correlation between the 3*I, the SIQR, and the SF-12 was assessed. The reliability of the 3*I was examined by internal consistency (the Cronbach's alpha coefficient) and intraclass correlation coefficient (ICC). Results: In all 196 patients participated in the study. The mean (SD) age of patients was 45.62 ± 10.70 years. Several significant correlations between the Invalidation Illness Inventory (discounting/lack of understanding) with the symptom impact (SIQR) and the short form health survey (SF-12) were observed lending support to the convergent validity of the 3*I. The Cronbach’s alpha coefficients were acceptable for most dimensions and sources, ranging from 0.52 to 0.88. Most ICC values for the dimensions of 3*I were above 0.75. Conclusions: The findings indicated that the Persian version of Illness Invalidation Inventory (3*I) is a valid instrument for invalidation assessment in patients with chronic pain. Given the high frequency of perceived invalidation among patients with rheumatic painful disorders, serious attention is needed to the issue in clinical and research settings.
- Open Access
- 22 December 2021
- Published by Wiley in ACR Open Rheumatology
- Vol. 4 (3) , 260-268
Implication of the Nociplastic Features for Clinical Diagnosis of Fibromyalgia: Development of the Preliminary Nociplastic‐Based Fibromyalgia Features (NFF) Tool
Objective: Nociplastic concept incorporates a broad continuum of pain phenotypes shared with clinical peculiarity. This study aimed to develop and validate a diagnostic tool, the preliminary Nociplastic‐based Fibromyalgia Features (NFF), to detect fibromyalgia (FM) in patients with chronic pain.Methods: Items requiring yes or no responses and relating to the most relevant clinical nociplastic pain (NP) features of FM were compiled by a group of expert rheumatologists. The provisional list was tested in a prospective study on 185 consecutive patients with chronic pain (126 patients with FM and 59 patients with non‐FM non‐inflammatory chronic pain) diagnosed based on expert decision. Identification of the most discriminant combinations of items for FM and the calculation of their sensitivity and specificity were based on both univariate and multivariate (stepwise logistic regression) analyses. All participants were investigated through the final NFF, the 2011 American College of Rheumatology (ACR) criteria, and the 2016 ACR criteria. NFF performance was assessed with receiver operating characteristic curve analysis.Results: Based on multivariate analyses, we retained only seven items in the final version of the NFF. A cut‐off score of 4 (corresponding to the number of positive items) gave the highest rate of correct identification of patients (85%), with a sensitivity of 82% and a specificity of 91%. The NFF showed the highest concordance rate with expert diagnosis (85%) and the lowest value (77%) with the ACR 2016 criteria.Conclusion: The preliminary NFF with respect to the various aspects of NP showed good performance for detection of the FM in the clinical setting. This tool may provide a more pragmatic approach to the timely diagnosis of FM.
- 22 December 2021
- Published by Wiley in ACR Open Rheumatology
- Vol. 4 (3) , 260-268
Open AccessImplication of the Nociplastic Features for Clinical Diagnosis of Fibromyalgia: Development of the Preliminary Nociplastic‐Based Fibromyalgia Features (NFF) Tool
Objective: Nociplastic concept incorporates a broad continuum of pain phenotypes shared with clinical peculiarity. This study aimed to develop and validate a diagnostic tool, the preliminary Nociplastic‐based Fibromyalgia Features (NFF), to detect fibromyalgia (FM) in patients with chronic pain.Methods: Items requiring yes or no responses and relating to the most relevant clinical nociplastic pain (NP) features of FM were compiled by a group of expert rheumatologists. The provisional list was tested in a prospective study on 185 consecutive patients with chronic pain (126 patients with FM and 59 patients with non‐FM non‐inflammatory chronic pain) diagnosed based on expert decision. Identification of the most discriminant combinations of items for FM and the calculation of their sensitivity and specificity were based on both univariate and multivariate (stepwise logistic regression) analyses. All participants were investigated through the final NFF, the 2011 American College of Rheumatology (ACR) criteria, and the 2016 ACR criteria. NFF performance was assessed with receiver operating characteristic curve analysis.Results: Based on multivariate analyses, we retained only seven items in the final version of the NFF. A cut‐off score of 4 (corresponding to the number of positive items) gave the highest rate of correct identification of patients (85%), with a sensitivity of 82% and a specificity of 91%. The NFF showed the highest concordance rate with expert diagnosis (85%) and the lowest value (77%) with the ACR 2016 criteria.Conclusion: The preliminary NFF with respect to the various aspects of NP showed good performance for detection of the FM in the clinical setting. This tool may provide a more pragmatic approach to the timely diagnosis of FM.
- Open Access
- 30 November 2021
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 19 (4) , 712-720
Effects of Iron Supplementation on Attention Deficit Hyperactivity Disorder in Children Treated with Methylphenidate
Sepehr Tohidi, Elham Bidabadi, Mohammad-Javad Khosousi, Melika Amoukhteh, Maryam Kousha, Parham Mashouf, Tamkin Shahraki. Clin Psychopharmacol Neurosci 2021;19:712-20. https://doi.org/10.9758/cpn.2021.19.4.712
- 30 November 2021
- Published by Korean College of Neuropsychopharmacology in Clinical Psychopharmacology and Neuroscience
- Vol. 19 (4) , 712-720
Open AccessEffects of Iron Supplementation on Attention Deficit Hyperactivity Disorder in Children Treated with Methylphenidate
Sepehr Tohidi, Elham Bidabadi, Mohammad-Javad Khosousi, Melika Amoukhteh, Maryam Kousha, Parham Mashouf, Tamkin Shahraki. Clin Psychopharmacol Neurosci 2021;19:712-20. https://doi.org/10.9758/cpn.2021.19.4.712
- 22 August 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (1) , 245-254
No effect of approved fibromyalgia drugs on the social pain (invalidation) contrary to physical pain: an open-label short-term randomized clinical trial
Objectives The social pain or invalidation denoting painful feeling following social conflicts or misunderstanding about illness legitimacy has been proposed as a salient disabling symptom besides physical pain or non-pain symptoms in fibromyalgia (FM). We sought to evaluate the effect of 1-month administration of duloxetine or pregabalin on the invalidation dimensions in FM patients with respect to the comparison of these two drugs on this issue. Method This open-label randomized clinical trial study was performed on FM patients whose diagnoses were confirmed by a rheumatologist based on the 2016 American College of Rheumatology (ACR). Primary outcome measure (Illness Invalidation Inventory (3*I)) and secondary outcome measures (Beck Depression Inventory-II (BDI-II), widespread pain index (WPI), and polysymptomatic distress scale (PSD)) were compared before and after treatment, using paired t test or Wilcoxon signed test. Results Of 81 eligible FM patients, 44 patients in the duloxetine arm and 27 patients in the pregabalin arm completed the study protocol. Overall, no significant improvement was seen in 3*I scores after treatment with either duloxetine or pregabalin, except in the lack of understanding of medical professionals which improved after treatment with pregabalin (2.43 ± 1.38 to 1.79 ± 0.94, p value: 0.01). There were no intragroup and intergroup differences in the effects of duloxetine and pregabalin on 3*I scores when adjusted with the cofounders. Both duloxetine and pregabalin improved WPI, BDI-II, and PSD scores significantly. Conclusions Short-term FM pharmacological treatment had no effect on social pain. This finding was regardless of drug type, improvement of physical pain, and depression. Key Points • Social pain may behave as an independent but influential factor in FM rather than physical pain and depression. • Approved FM medications do not seem to change predictably the invalidation perception, which is a crucial factor in chronicity and maintaining of FM symptoms. • Dedicated approach to social pain seems necessary for the depiction of future successful therapeutic plan in FM.
- 22 August 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (1) , 245-254
No effect of approved fibromyalgia drugs on the social pain (invalidation) contrary to physical pain: an open-label short-term randomized clinical trial
Objectives The social pain or invalidation denoting painful feeling following social conflicts or misunderstanding about illness legitimacy has been proposed as a salient disabling symptom besides physical pain or non-pain symptoms in fibromyalgia (FM). We sought to evaluate the effect of 1-month administration of duloxetine or pregabalin on the invalidation dimensions in FM patients with respect to the comparison of these two drugs on this issue. Method This open-label randomized clinical trial study was performed on FM patients whose diagnoses were confirmed by a rheumatologist based on the 2016 American College of Rheumatology (ACR). Primary outcome measure (Illness Invalidation Inventory (3*I)) and secondary outcome measures (Beck Depression Inventory-II (BDI-II), widespread pain index (WPI), and polysymptomatic distress scale (PSD)) were compared before and after treatment, using paired t test or Wilcoxon signed test. Results Of 81 eligible FM patients, 44 patients in the duloxetine arm and 27 patients in the pregabalin arm completed the study protocol. Overall, no significant improvement was seen in 3*I scores after treatment with either duloxetine or pregabalin, except in the lack of understanding of medical professionals which improved after treatment with pregabalin (2.43 ± 1.38 to 1.79 ± 0.94, p value: 0.01). There were no intragroup and intergroup differences in the effects of duloxetine and pregabalin on 3*I scores when adjusted with the cofounders. Both duloxetine and pregabalin improved WPI, BDI-II, and PSD scores significantly. Conclusions Short-term FM pharmacological treatment had no effect on social pain. This finding was regardless of drug type, improvement of physical pain, and depression. Key Points • Social pain may behave as an independent but influential factor in FM rather than physical pain and depression. • Approved FM medications do not seem to change predictably the invalidation perception, which is a crucial factor in chronicity and maintaining of FM symptoms. • Dedicated approach to social pain seems necessary for the depiction of future successful therapeutic plan in FM.
- 7 January 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (6) , 2369-2376
Implication of invalidation concept in fibromyalgia diagnosis
Objectives The invalidation or social pain is an important but neglected issue in polysymptomatology of fibromyalgia (FM). This study sought whether tracing-perceived invalidation could be effective to discriminate between the presence and absence of FM in chronic pain patients with respect to five different sources, including spouses, family, colleagues, health professionals, and social services. Methods A total of 207 consecutive chronic pain patients were evaluated for the presence of FM by rheumatologic assessment. Invalidation was measured by the Illness Invalidation Inventory (3*I). Receiver operator characteristic (ROC) analyses were used to evaluate the ability of 3*I dimensions and sources to discriminate having FM among chronic pain patients. Binary logistic regression analyses were performed. Results The perceived discounting and lack of understanding from spouse and family sources were higher in FM rather than non-FM patients. ROC analyses demonstrated that invalidation dimensions stemming from spouse and family could appropriately discriminate between the presence and absence of FM. The area under the curve (AUC) for other sources showed non-significant values. Adjusted logistic regression analysis by age, education level, and work status showed that discounting by family and lack of understanding by the spouse could be significant predictors of FM (OR 2.30; 95% CI 1.29–4.11, P = 0.005; OR 1.72; 95% CI 1.08–2.74, P = 0.022, respectively). Conclusions This study elucidated the discriminatory power of invalidation in identification of FM from non-FM patients, especially when originated from spouse and family. Our results provide a basis to propose the invalidation as a salient component in the FM dictionary parallel to other famous FM symptoms. Key Points • The incorporation of newly highlighted social definition of pain seems warranted in the pain practice. • Despite proposing invalidation in painful conditions, its diagnostic role in FM remains unexplored. • Acknowledging of invalidation or social pain in polysymptomatology of FM could shift the paradigm of diagnosis of FM.
- 7 January 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (6) , 2369-2376
Implication of invalidation concept in fibromyalgia diagnosis
Objectives The invalidation or social pain is an important but neglected issue in polysymptomatology of fibromyalgia (FM). This study sought whether tracing-perceived invalidation could be effective to discriminate between the presence and absence of FM in chronic pain patients with respect to five different sources, including spouses, family, colleagues, health professionals, and social services. Methods A total of 207 consecutive chronic pain patients were evaluated for the presence of FM by rheumatologic assessment. Invalidation was measured by the Illness Invalidation Inventory (3*I). Receiver operator characteristic (ROC) analyses were used to evaluate the ability of 3*I dimensions and sources to discriminate having FM among chronic pain patients. Binary logistic regression analyses were performed. Results The perceived discounting and lack of understanding from spouse and family sources were higher in FM rather than non-FM patients. ROC analyses demonstrated that invalidation dimensions stemming from spouse and family could appropriately discriminate between the presence and absence of FM. The area under the curve (AUC) for other sources showed non-significant values. Adjusted logistic regression analysis by age, education level, and work status showed that discounting by family and lack of understanding by the spouse could be significant predictors of FM (OR 2.30; 95% CI 1.29–4.11, P = 0.005; OR 1.72; 95% CI 1.08–2.74, P = 0.022, respectively). Conclusions This study elucidated the discriminatory power of invalidation in identification of FM from non-FM patients, especially when originated from spouse and family. Our results provide a basis to propose the invalidation as a salient component in the FM dictionary parallel to other famous FM symptoms. Key Points • The incorporation of newly highlighted social definition of pain seems warranted in the pain practice. • Despite proposing invalidation in painful conditions, its diagnostic role in FM remains unexplored. • Acknowledging of invalidation or social pain in polysymptomatology of FM could shift the paradigm of diagnosis of FM.